We are live on
!
Find out more
FA
Forefront Analytics Portfolio holdings
AUM
$110M
1-Year Est. Return
18.54%
This Fund
S&P 500
This Quarter
Est. Return
+6.93%
1 Year Est. Return
+18.54%
3 Year Est. Return
+33.55%
5 Year Est. Return
+24.76%
10 Year Est. Return
–
AUM
$188M
AUM Growth
-$119K
(-0.06%)
Cap. Flow
-$12.7M
Cap. Flow
% of AUM
-6.78%
Top 10 Holdings %
Top 10 Hldgs %
60.18%
Holding
81
New
15
Increased
22
Reduced
35
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$4.6M |
| 2 |
Invesco Dorsey Wright Momentum ETF
PDP
|
+$2.65M |
| 3 |
State Street Real Estate Select Sector SPDR ETF
XLRE
|
+$1.08M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$906K |
| 5 |
Invesco BulletShares 2030 Corporate Bond ETF
BSCU
|
+$778K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nuveen ESG Large-Cap Value ETF
NULV
|
+$5.9M |
| 2 |
iShares Currency Hedged MSCI Emerging Markets
HEEM
|
+$5.07M |
| 3 |
iShares MSCI USA Momentum Factor ETF
MTUM
|
+$3.8M |
| 4 |
iShares Core S&P 500 ETF
IVV
|
+$1.84M |
| 5 |
HDV
iShares Core High Dividend ETF
HDV
|
+$1.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 1.26% |
| 2 | Industrials | 0.26% |
| 3 | Financials | 0.24% |
| 4 | Technology | 0.19% |
| 5 | Real Estate | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Pfizer
PFE
$143B
| $327K | 0.17% |
6,387
-1,187
| -16% | -$56.9K |
|
52
iShares MSCI Emerging Markets ETF
EEM
$28B
| $294K | 0.16% |
+7,748
| New | +$286K |
|
53
Abbott
ABT
$175B
| $289K | 0.15% |
+2,626
| New | +$272K |
|
54
iShares Global REIT ETF
REET
$5.05B
| $282K | 0.15% |
+12,431
| New | +$277K |
|
55
UnitedHealth
UNH
$387B
| $279K | 0.15% |
524
-138
| -21% | -$73.1K |
|
56
Medtronic
MDT
$106B
| $279K | 0.15% |
+3,589
| New | +$291K |
|
57
Incyte
INCY
$23.4B
| $266K | 0.14% |
+3,311
| New | +$253K |
|
58
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$16.9B
| $264K | 0.14% |
+3,579
| New | +$264K |
|
59
iShares ESG Aware MSCI EM ETF
ESGE
$6.47B
| $248K | 0.13% |
8,259
+14
| +0.2% | +$410 |
|
60
Regeneron Pharmaceuticals
REGN
$70.9B
| $221K | 0.12% |
307
-8
| -3% | -$5.9K |
|
|
PSTX
61
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $80.9K | 0.04% |
15,270
-380
| -2% | -$1.74K |
|
62
Annexon
ANNX
$950M
| $79.9K | 0.04% |
15,456
-599
| -4% | -$3.29K |
|
|
LONA
63
LeonaBio Inc
LONA
$67.8M
| $70.9K | 0.04% |
+2,235
| New | +$70.4K |
|
64
Dyadic International
DYAI
$45.9M
| $70.2K | 0.04% |
57,094
+16,548
| +41% | +$28.3K |
|
65
Geron
GERN
$924M
| $65.1K | 0.03% |
26,897
+9,311
| +53% | +$20.9K |
|
|
ORTX
66
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $61.2K | 0.03% |
16,489
+6,485
| +65% | +$28.7K |
|
|
MREO
67
Mereo BioPharma
MREO
$49.5M
| $55.1K | 0.03% |
73,500
-39,300
| -35% | -$32.3K |
|
68
Jasper Therapeutics
JSPR
$24.8M
| $55.1K | 0.03% |
11,400
-580
| -5% | -$3.88K |
|
|
SURF
69
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $52K | 0.03% |
63,356
-3,482
| -5% | -$3.43K |
|
|
CDAK
70
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
| $39.7K | 0.02% |
99,935
+43,450
| +77% | +$28.6K |
|
71
CytomX Therapeutics
CTMX
$788M
| $39.7K | 0.02% |
24,787
-23,082
| -48% | -$34.1K |
|
|
DM
72
DELISTED
Desktop Metal, Inc.
DM
| $29K | 0.02% |
2,131
| – | – |
|
|
ACHL
73
DELISTED
Achilles Therapeutics
ACHL
| $27.5K | 0.01% |
30,525
-1,675
| -5% | -$2.82K |
|
|
ADAM
74
Adamas Trust
ADAM
$807M
| $25.6K | 0.01% |
2,500
| – | – |
|
|
EIGR
75
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $14.6K | 0.01% |
+413
| New | +$49.6K |
|
Similar funds
NC
PXPO
OWA
MCM
AC
NA
NMC
BCM
Forefront Analytics's Q4 2022 Portfolio in Review
As of Q4 2022, Forefront Analytics held 81 positions worth $188M, down 0.06% from $188M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Forefront Analytics withdrew a net $12.7M in Q4 2022, closing 6 positions and reducing 35 holdings. Its most notable exit was Johnson & Johnson, an estimated $307K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 1.3% of assets, up from 1.2% a quarter earlier, followed by Industrials and Financials.
Against the trend, Forefront Analytics opened a new position in Invesco Dorsey Wright Momentum ETF worth $2.58M.
- Forefront Analytics's largest Q4 2022 buy was Invesco Dorsey Wright Momentum ETF: 36,352 shares worth $2.58M.
- Forefront Analytics added most to Vanguard FTSE Emerging Markets ETF in Q4 2022, an estimated $4.6M increase.
- Forefront Analytics's biggest Q4 2022 reduction was Nuveen ESG Large-Cap Value ETF, cutting an estimated $5.9M.
- Forefront Analytics fully exited Johnson & Johnson in Q4 2022, selling an estimated $307K.
- Forefront Analytics's ten largest holdings make up 60% of its $188M portfolio in Q4 2022.
- Forefront Analytics opened 15 new positions and closed 6 in Q4 2022.
- Forefront Analytics's portfolio value fell 0.06% quarter-over-quarter to $188M.
Based on Forefront Analytics's 13F filing for Q4 2022, filed 13 Feb 2023.